IBS-D
FDA Determines REMS for Alosetron No Longer Necessary
The FDA has determined Risk Evaluation and Mitigation Strategies for the irritable bowel syndrome drug alosetron ...
SEPTEMBER 14, 2023
Tips for Treating Challenge Cases of IBS-D
Although the treatment of diarrhea-predominant irritable bowel syndrome is a core component of gastroenterology ...
MAY 20, 2023
IgG-Based Elimination Diets Help Patients With IBS
CHARLOTTE, N.C.—A new immunoglobulin G?based diet improved outcomes in patients with irritable bowel syndrome ...
JANUARY 9, 2023
Opioid Agonist Relieves IBS-D Pain in Trial
Banff, Alberta—New research indicates that the novel agent eluxadoline is effective for treating abdominal ...
JULY 26, 2019
Load more